Dr. Emanuel Bosi, Professor of Internal Medicine, Vita-Salute San Raffaele University, Milan & Head, General Medicine, Diabetes & Endocrinology Unit, San Raffaele Hospital Scientific Institute, Milan will be visiting Obaidallah Hospital, Ministry of Health in UAE on 25^th – 28^th February 2019. Find location map here: https://bit.ly/2txM5GJ

Dr. Bosi will hold seminars on Beyond glycated hemoglobin and New glucose metrics in Diabetes during the visit at the Obaidallah Hospital.
Read more on http://www.mohap.gov.ae/en/services/Pages/VisitingDoctors.aspx

Dr. Emanuele Bosi received his M.D. degree, at University of Milan 1979 and got a Diploma in Diabetes and Metabolic Diseases 1983, University of Milan. He is a certified Medical Practitioner since 1985 at the General Medical Council, UK.  From 2002 to date he is the Head, General Medicine, Diabetes and Endocrinology Unit, San Raffaele University Hospital and Research Institute, Milan. And he worked as the Director of Diabetes Research Institute (DRI), at the same institute over the last four years. His areas of expertise are Diabetes & Endocrinology and he holds an extraordinary curriculum of research projects and publications.

The Diabetes Research Institute (DRI) is composed of 8 units of basic research and 5 groups of clinical research. The DRI is an international center of excellence of prevention and treatment of diabetes. It is part of the International DRI federation (DRI-NET), which includes 12 other DRI’s around the world.

The most recent and innovative program include the development of modern technologies (eg. Insulin pumps and artificial pancreas), the study and prevention of diabetes complications and programs of cardio-diabetes and cardio-metabolism in type 2 diabetes.

A breakthrough research is focused on the prevention and cure of Diabetes Type 1 (T1D). To achieve this objective, two specific programs are pursued, both of which take advantage of patients and animal models:

1. Prediction and prevention of T1D: aims at defining pathogenetic mechanisms of induction and perpetuation of autoimmunity and developing strategies for halting/reverting the progression to T1D.

1. Beta cell replacement and cell therapy in T1D: aims at developing novel immune tolerance-inducing, immunosuppression-lightening and islet-regeneration therapies to prolong the survival of native and/or transplanted beta cells.

Read more about the Diabetes Research Institute at San Raffaele University Hospital: http://research.hsr.it/en/institutes/diabetes-research-institute/index.html